Drugs / DNA Mosaic env
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02296541 | Dec 2014 → Nov 2016 | HIV infectious disease | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | DNA Mosaic env | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02296541 ↗ |
| Modality | Vaccine | “a trivalent global mosaic, a group M consensus (CON-S), or a natural clade B (Nat-B) gp160 env DNA vaccine” PMID 36787249 ↗ Feb 2023 |
| Route | Intramuscular | “4 mg to be administered as 1 mL IM” NCT02296541 ↗ |